Researchers at the Francis Crick Institute, the University of Cambridge, Imperial College London, the University of Liverpool, the University of Cape Town and UKHSA have uncovered a link between an antiviral drug for COVID-19 infections called molnupiravir and a pattern of mutations in the SARS-CoV-2 virus.
As a result of vaccination or infection, our immune system produces antibodies that attach to the spike protein of SARS-CoV-2, preventing the virus from entering and replicating within cells.
White-tailed deer across Ohio have been infected with the virus that causes COVID-19, new research has found – and the results also show that viral variants evolve about three times faster in deer than in humans.
A two-year study found that spikes of post-vaccination SARS-CoV-2 viral infections (commonly known as COVID-19 breakthrough cases) remain common, yet hospitalization rates have dramatically dropped following the first wave of the virus’ omicron subvariant.
Researchers at Vanderbilt University Medical Center have received a four-year, $28 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health, to study the relationship between COVID-19 and diabetes.
Long Covid, which affects nearly two-million people in the UK (1), is not caused by an immune inflammatory reaction to COVID-19, University of Bristol-led research finds. Emerging data demonstrates that immune activation may persist for months after COVID-19.
Critical insights into why airborne viruses lose their infectivity have been uncovered by scientists at the University of Bristol. The findings, published in the Journal of the Royal Society Interface today [20 June], reveal how cleaner air kills the virus significantly quicker and why opening a window may be more important than originally thought. The research could shape future mitigation strategies for new viruses.
Cytomegalovirus (CMV) is one of the most prevalent herpesviruses worldwide. Depending on the geographical area, it can affect between 40% and 90% of the population and, although it does not produce symptoms in healthy people, the control of this chronic infection requires constant work by the immune system, which is constantly fighting to keep it at bay.
T cells are thought to be important for control of SARS-CoV-2 infection, but little is known about the host factors that promote T cell responses in the respiratory tract. We used non-human primates to investigate the regulation of respiratory immunity…
A study published April 11 in the Journal of the American Medical Association (JAMA) evaluated two drugs that act on the renin-angiotensin system (RAS) as potential treatments for severe COVID-19. Severe acute respiratory syndrome coronavirus2 (SARS-CoV-2), the virus that causes COVID-19, enters pulmonary and myocardial cells through binding of its spike protein to the human angiotensin-converting enzyme 2 (ACE2). ACE2 is a vital enzyme that controls blood pressure and blood flow to multiple organs, including the lungs, heart and kidneys.
The human body is capable of creating a vast, diverse repertoire of antibodies—the Y-shaped sniffer dogs of the immune system that can find and flag foreign invaders.
Researchers have shown that, in two cases, COVID-19 infection breached the placenta and caused brain damage in the newborn.
Booster vaccinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being promoted worldwide to counter the coronavirus disease 2019 (COVID-19) pandemic.
Experts from the University of Barcelona, the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), the Institute of Microelectronics of Barcelona (IMB-CNM-CSIC) and the Aragon Nanoscience and Materials Institute of Aragon (INMA) —a joint institute of the CSIC and the University of Zaragoza— have developed a new method to detect RNA viruses based on the triplex-forming probe technology.
Various long-term effects have been found to occur after infection by the novel coronavirus (COVID-19), and the reality of these lingering symptoms remains unknown.
Researchers from the Icahn School of Medicine at Mount Sinai have generated the first induced pluripotent stem cells (iPSCs) from bats, gaining valuable insights into the close relationship between bats and viruses.
Analyzing the most extensive datasets in the U.S., researchers from the Icahn School of Medicine at Mount Sinai have revealed that vaccination against COVID-19 is associated with fewer heart attacks, strokes, and other cardiovascular issues among people who were infected with SARS-CoV-2, the virus that causes COVID-19. The research letter, “Impact of Vaccination on Major Adverse Cardiovascular Events in Patients with COVID-19 Infection,” was published in the Journal of the American College of Cardiology on February 20. The research will also be presented on March 5, 2023 in a poster session in New Orleans, LA, at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology.
ROCKVILLE, MD – The virus that causes COVID-19, called SARS-CoV-2, uses its spike protein in order to stick to and infect our cells. The final step for the virus to enter our cells is for part of its spike protein to act like a twist tie, forcing the host cell’s outer membrane to fuse with the virus. Kailu Yang, in the lab of Axel Brunger, colleagues at Stanford University, and collaborators at University of California Berkely, Harvard Medical School, and University of Finland have generated a molecule based on the twisted part of the spike protein (called HR2), which sticks itself onto the virus and prevents the spike protein from twisting.
Smoking tobacco and vaping electronic cigarettes may increase healthy young people’s risk for developing severe COVID illness.
Breakthrough COVID-19 infections after vaccination occurred in 7.5% of Texans surveyed and were linked to Hispanic ethnicity, larger household size, rural versus urban living, type of vaccination, and multiple comorbidities, according to findings from UTHealth Houston School of Public Health published today in the Journal of Infectious Diseases.
Christian Bréchot, MD, PhD, President of the Global Virus Network (GVN), Associate Vice President for International Partnerships and Innovation at the University of South Florida and Professor of the Division of Infectious Disease, Department of Internal Medicine at USF Health Morsani College of Medicine, the GVN Southeast U.S. Regional Headquarters today issued a statement on the surge of SARS-CoV-2.
Breaking research demonstrates the efficacy of two data analytics-based strategies that clinical labs employed to meet COVID-19 testing demands during the height of the pandemic. These findings, published in the Data Science Issue of AACC’s The Journal of Applied Laboratory Medicine, give labs a blueprint for using data analytics to ensure patient access to testing during future infectious disease outbreaks.
MEDIA ADVISORY UNDER EMBARGO UNTIL DECEMBER 21, 2022 in Cell Systems Corresponding Authors: Elena Zaslavsky, PhD, Associate Professor of Neurology, Icahn School of Medicine at Mount Sinai; Steven H. Kleinstein, PhD, Anthony Brady Professor of Pathology at Yale School of…
When patients undergo any type of surgery after having had COVID, their odds of significant postoperative problems diminish with elapsed time from COVID diagnosis.
Researchers at Vanderbilt University Medical Center now report that this trend of decreasing risk persists longer than previously known, for as long as 13 months after surgery. Their report appeared Dec. 14 in JAMA Network Open.
Study is one of the first to associate long COVID symptoms with changes in gene expression during acute COVID-19
By August 2022, most children and adults younger than 60 years in Canada had been exposed to SARS-CoV-2 through a combination of vaccination and infection, according to a large study looking at blood antibodies published in CMAJ (Canadian Medical Association Journal)
The study, a collaboration between Clover and the International Vaccine Institute, showed that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household member had received SCB-2019 (CpG 1018/Alum) compared to placebo
Researchers of the University of Bristol-led study, published in Science Advances today [23 November], say their findings could lead to the development of a pan-coronavirus treatment to defeat all coronaviruses.
Three currently circulating omicron subvariants of SARS-CoV-2 – including two that currently make up almost 50% of reported COVID-19 infections in the U.S. – are better at evading vaccine- and infection-generated neutralizing antibodies than earlier versions of omicron, new research suggests.
A subset of healthcare workers vaccinated against COVID-19 had unexpectedly low responses to the immunizations, according to Cedars-Sinai investigators. The findings of the new study are published in iScience, a Cell Press journal.
Dysregulation of macrophages during SARS-CoV-2 infection and the over-exuberant production of pro-inflammatory cytokines by these macrophages has been hypothesized to contribute to severity of COVID-19 disease.
A new study from the Lab of Fangqiong Ling at the McKelvey School of Engineering will help facilitate the exchange of data and results between engineers and medical researchers, leading to a more robust understanding of the relationships between viruses moving through the engineered world and diseases spreading through populations.
Researchers in Germany have discovered that age-dependent impairments in antiviral interferon proteins underlie the increased susceptibility of older patients to severe COVID-19. The study, published today in the Journal of Experimental Medicine (JEM), shows that aged mice infected with SARS-CoV-2 are protected from severe disease by treatment with one of these interferons, IFN-γ.
Over the past two years, scientists have studied the SARS-CoV-2 virus in great detail, laying the foundation for developing COVID-19 vaccines and antiviral treatments. Now, for the first time, scientists at the Department of Energy’s SLAC National Accelerator Laboratory have seen one of the virus’s most critical interactions, which could help researchers develop more precise treatments.
Mount Sinai researchers have produced a high-resolution crystal structure of an enzyme essential to the survival of SARS-CoV-2, the virus that causes COVID-19. The discovery could lead to the design of new antivirals to combat current and future coronaviruses.
Neutralizing antibody levels against the original COVID-19 virus and omicron variants in vaccinated adults tend to decline by at least 15% per month after a single booster shot, a new study using serum from human blood samples suggests.
Investigators at Cedars-Sinai have proposed a theory for how SARS-CoV-2, the virus that causes COVID-19, infects the body. Their hypothesis, published in Frontiers in Immunology, could explain why some people still have symptoms long after the initial infection.
A UC San Diego-led program that monitors wastewater for the presence of SARS-CoV-2 and which has effectively predicted subsequent surges in COVID-19 cases in San Diego has been expanded to detect the presence of monkeypox.
Article title: Chemokines, soluble PD-L1 and immune cell hyporesponsiveness are distinct features of SARS-CoV-2 critical illness Authors: Eric D. Morrell, Pavan K. Bhatraju, Neha A. Sathe, Jonathan Lawson, Linzee Mabrey, Sarah E. Holton, Scott R. Presnell, Alice Wiedeman, Carolina Acosta-Vega,…
About The Study: Researchers found that 4-dose recipients of the Pfizer-BioNTech vaccine had a lower risk of acquiring COVID-19 than 3-dose recipients during the peak Omicron variant wave in this study of 29,000 health care workers in Israel. Authors: Allon E. Moses,…
Two studies presented today at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo reveal how SARS-CoV-2 antibody levels vary among recipients of COVID-19 vaccines and naturally infected individuals. These findings add to a growing body of knowledge that is essential for guiding public health initiatives, and that might one day enable clinicians to assess individuals’ immunity to SARS-CoV-2.
For a glimpse into the future of SARS-CoV-2 immunity, scientists at La Jolla Institute for Immunology (LJI) are investigating how the immune system builds its defenses against common cold coronaviruses (CCCs).
A MedUni Vienna research team has developed a new blood test that indicates a person’s status of cellular immunity to SARS-CoV-2 within just 48 hours.
To develop new COVID-19 medications, researchers are working to target nsp13, a protein coronaviruses need to replicate. In ACS Infectious Diseases, researchers describe a new approach to identifying molecules that interfere with this protein, a step toward developing pan-coronavirus antivirals.
Scientists and physicians at UC San Diego and Scripps Research describe how wastewater sequencing provided dramatic new insights into levels and variants of SARS-CoV-2 on campus and in the broader community — a key step to public health interventions in advance of COVID-19 case surges.
Mount Sinai-led researchers have shown that tiny, robust immune particles derived from the blood of a llama could provide strong protection against every COVID-19 variant, including Omicron, and 18 similar viruses.
A $10 million grant over four years will support further examination of a national study looking at COVID-19 vaccination safety during pregnancy and immune response pre-and post-delivery for both mom and baby.
Mount Sinai researchers have developed a machine learning algorithm that can determine if an individual has SARS-CoV-2 infections, the virus that causes COVID-19—with a high sensitivity and specificity—from the data collected by wearable devices.
Although the different SARS-CoV-2 variants currently in circulation are undoubtedly less severe in vaccinated individuals in the general population, immunocompromised people are at greater risk of developing severe forms of COVID-19.
Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM). The antibodies were effective against all SARS-CoV-2 variants of concern tested and could be used alone or in an antibody cocktail to diminish the risk of infection.